McCore Medicine-B: First case enrolled in Phase Ib/II trial of MT1002 AIS completed.

Announcement from McPharma-B: The company's independently developed candidate drug MT1002 for the treatment of acute ischemic stroke has recently completed the enrollment of the first subject in the phase Ib/II clinical trial, marking the official entry into the substantive execution phase of this key registration clinical study. This trial is divided into two parts, the first part being a multicenter clinical study to evaluate the safety, efficacy, and pharmacokinetic characteristics of MT1002, and the second part being a multicenter, randomized, standard treatment controlled clinical study. The first subject enrolled is the first subject enrolled in the first part.